In addition to our regular features, this issue of The CMTA Report is packed with these articles and items of interest:

  • Novartis Acquires CMT1A Drug Maker DTx Pharma
  • Treatments for CMT2D Show Promise in Mouse Models
  • CMT2C Patient Focus Group
  • Celebrating Awareness Month
  • Neurotoxic Drug List Updated
  • Camp Footprint East and West